In an attempt to expand its neurology portfolio, Collegium Pharmaceuticals has agreed to acquire Ironshore Therapeutics for US$525 M. Through the takeover, Collegium will gain access to Ironshore’s commercial asset Jornay PM® (methylphenidate HCl), an extended-release prescription medicine indicated for treating attention deficit hyperactivity disorder (ADHD) in individuals six years of age and older. According to a company source, Jornay PM is set to become Collegium’s main growth driver, with expected net revenue exceeding US$100 M in 2024.